About Cidqo
Cidqo is a Healthcare company based in Barcelona (Spain) founded in 2012, and was acquired by Suanfarma in March 2013. Pharmaceuticals and intermediates are developed using combinatorial chemistry. Cidqo offers products and services including Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is CIDQO 2012, SL.
Company details
Cidqo was established in 2012 in Barcelona, Spain, within the pharmaceuticals sector. Combinatorial chemistry is employed for developing active pharmaceutical ingredients and intermediates. Services in API production are provided, with completed developments including N-Acetyl Cysteine (NAC), L-Carnosine, Dapoxetine, Tenofovir, Rivastigmine, and Diacerein. Ongoing efforts focus on Cinacalcet HCL, Adenine, and Emtricitabine.
Products & Services of Cidqo
Cidqo offers a comprehensive portfolio of products and services, including Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance.
Designs synthetic routes for APIs and intermediates.
Develops and validates methods for HPLC and spectroscopy.
Evaluates patents and innovative chemical routes.
Provides regulatory support and process optimization.
Funding Insights of Cidqo
- Total Rounds 2
- Last Round Grant β $55,006
- First Round $56,000
(May 2015)
- Investors Count 2
All 2 funding rounds of Cidqo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $55,006 | Grant | β | β | |
| May 2015 | $56,000 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Cidqo
Cidqo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Suanfarma, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Generics, nutraceuticals, and APIs are developed by Suanfarma. | 1993 | suanfarma.com | Madrid, Spain |
Investor details for Cidqo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cidqo
4 dated milestones of Cidqo across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Cidqo is founded.
- Exit Acquired by Suanfarma.
- Funding First funding round of $56K.
- Funding Latest funding round, Grant, of $55K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cidqo
Cidqo was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Cidqo is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Cidqo was established in 2012 in Barcelona, Spain, within the pharmaceuticals sector. Combinatorial chemistry is employed for developing active pharmaceutical ingredients and intermediates. Services in API production are provided, with completed developments including N-Acetyl Cysteine (NAC), L-Carnosine, Dapoxetine, Tenofovir, Rivastigmine, and Diacerein. Ongoing efforts focus on Cinacalcet HCL, Adenine, and Emtricitabine.
Cidqo offers Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance.
Cidqo has 3 investors. Key investors include Suanfarma, European Union, and EIC Fund.
Cidqo operates through Cidqo 2012, Sl.
Yes. Cidqo was acquired by Suanfarma in March 2013.
